Eliglustat: A Review in Gaucher Disease Type 1
- 888 Downloads
Oral eliglustat (Cerdelga®) is approved in several countries for the long-term treatment of adults with Gaucher disease type 1 (GD1) who are cytochrome P450 (CYP) 2D6 extensive metabolizers (EMs), intermediate metabolizer (IMs) or poor metabolizers (PMs) [these three CYP categories encompass >90 % of individuals]. Eliglustat is a potent, selective inhibitor of glucosylceramide synthase, the rate-limiting enzyme in the synthesis of certain glycosphingolipids, and thus, reduces the rate of biosynthesis of glycosphingolipids to counteract the catabolic defect (i.e. substrate reduction therapy). In the 9-month phase 3 ENGAGE trial, eliglustat significantly improved haematological endpoints and reduced organomegaly compared with placebo in treatment-naive adults with GD1, with the bone marrow burden score (a marker of Gaucher cell infiltration) and GD1 biomarkers also improving from baseline in eliglustat recipients. After 12 months in the phase 3 ENCORE trial, oral eliglustat was noninferior to intravenous imiglucerase [an enzyme replacement therapy (ERT)] in maintaining disease stability in adults who had stable disease after receiving ERT for ≥3 years. During long-term treatment with eliglustat (≤4 years) in the extension period of each of these pivotal trials and a phase 2 trial, patients experienced sustained improvements in visceral, haematological and skeletal endpoints, with no new safety concerns identified. Further clinical experience will help to more definitively establish the position of eliglustat treatment in adults with GD1. In the meantime, with its convenient oral regimen, eliglustat is an emerging alternative therapy to ERT for the long-term treatment of adults with GD1 who are CYP2D6 EMs, IMs or PMs.
KeywordsEnzyme Replacement Therapy Liver Volume Fatigue Severity Scale Miglustat Spleen Volume
During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 3.Genzyme Corporation. Cerezyme® imiglucerase for injection: US prescribing information. 2011. www.cerezyme.com/. Accessed 5 Aug 2015.
- 5.European Medicines Agency. Cerdelga: summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 8 June 2015.
- 9.Genzyme Ireland Ltd. Cerdelga® (eliglustat) capsules, for oral use: US prescribing information. 2014. http://www.cerdelga.com/. Accessed 8 June 2015.
- 18.Giraldo P, Pleat R, Angell J, et al. Stability is maintained in adult patients with Gaucher disease type 1 (GD1) switched from velaglucerase alfa to eliglustat: a sub-analysis of the eliglustat, phase 3 ENCORE trial [abstract no. P-610]. J Inherit Metab Dis. 2015;38(Suppl 1):S296–7.Google Scholar
- 19.Mistry P, Amato DJ, Dasouki M, et al. ENGAGE - a phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: results after 18 months [abstract]. Mol Genet Metab. 2015;114(2):S81–2.CrossRefGoogle Scholar
- 20.Cox TM, Drelichman GI, Cravo R, et al. ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results [abstract]. Mol Genet Metab. 2015;114(2):S33–4.CrossRefGoogle Scholar
- 23.Lau H, Ibrahim J, Peterschmitt MJ, et al. Tremor and peripheral neuropathy are infrequent and non-serious events in Gaucher type 1 patients treated with eliglustat [abstract]. Mol Genet Metab. 2015;114(2):S69–70.Google Scholar
- 26.European Medicines Agency. Zavesca 100 mg hard capsules: summary of product characteristics. 2012. http://www.ema.europa.eu/. Accessed 26 June 2015.
- 27.Actelion Pharmaceuticals US Inc. Zavesca® (miglustat) capsules, for oral use: US prescribing information. 2014. http://www.zavesca.com/. Accessed 26 June 2015.